Investment analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a note issued to investors on Saturday. The firm set a “hold” rating on the medical research company’s stock.
Enzo Biochem Stock Performance
Shares of ENZ opened at $0.98 on Friday. The firm has a 50 day simple moving average of $1.12 and a two-hundred day simple moving average of $1.12. Enzo Biochem has a one year low of $0.93 and a one year high of $1.50.
Institutional Trading of Enzo Biochem
Several institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares during the period. XTX Topco Ltd boosted its holdings in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 13,735 shares during the last quarter. BBR Partners LLC acquired a new stake in Enzo Biochem during the 3rd quarter valued at approximately $112,000. Finally, Geode Capital Management LLC raised its holdings in Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the last quarter. Institutional investors own 36.90% of the company’s stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Recommended Stories
- Five stocks we like better than Enzo Biochem
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Tesla Investors Continue to Profit From the Trump Trade
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- With Risk Tolerance, One Size Does Not Fit All
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.